China
· Delayed Price · Currency is CNY Sirio Pharma Statistics
Total Valuation
Sirio Pharma has a market cap or net worth of CNY 5.94 billion. The enterprise value is 6.99 billion.
| Market Cap | 5.94B |
| Enterprise Value | 6.99B |
Important Dates
The last earnings date was Friday, April 18, 2025.
| Earnings Date | Apr 18, 2025 |
| Ex-Dividend Date | Jun 21, 2024 |
Share Statistics
Sirio Pharma has 235.60 million shares outstanding. The number of shares has decreased by -0.65% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 235.60M |
| Shares Change (YoY) | -0.65% |
| Shares Change (QoQ) | -0.78% |
| Owned by Insiders (%) | 20.72% |
| Owned by Institutions (%) | 20.84% |
| Float | 85.69M |
Valuation Ratios
The trailing PE ratio is 17.78 and the forward PE ratio is 15.14.
| PE Ratio | 17.78 |
| Forward PE | 15.14 |
| PS Ratio | 1.41 |
| PB Ratio | 2.19 |
| P/TBV Ratio | 3.59 |
| P/FCF Ratio | 19.22 |
| P/OCF Ratio | 8.45 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.46, with an EV/FCF ratio of 22.61.
| EV / Earnings | 21.14 |
| EV / Sales | 1.66 |
| EV / EBITDA | 10.46 |
| EV / EBIT | 16.33 |
| EV / FCF | 22.61 |
Financial Position
The company has a current ratio of 2.26, with a Debt / Equity ratio of 0.60.
| Current Ratio | 2.26 |
| Quick Ratio | 1.59 |
| Debt / Equity | 0.60 |
| Debt / EBITDA | 2.42 |
| Debt / FCF | 5.24 |
| Interest Coverage | 5.38 |
Financial Efficiency
Return on equity (ROE) is 9.87% and return on invested capital (ROIC) is 6.05%.
| Return on Equity (ROE) | 9.87% |
| Return on Assets (ROA) | 4.98% |
| Return on Invested Capital (ROIC) | 6.05% |
| Return on Capital Employed (ROCE) | 9.03% |
| Revenue Per Employee | 1.61M |
| Profits Per Employee | 126,695 |
| Employee Count | 2,610 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 5.52 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.85% in the last 52 weeks. The beta is 0.87, so Sirio Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | -12.85% |
| 50-Day Moving Average | 26.18 |
| 200-Day Moving Average | 25.71 |
| Relative Strength Index (RSI) | 47.53 |
| Average Volume (20 Days) | 3,058,561 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Sirio Pharma had revenue of CNY 4.21 billion and earned 330.67 million in profits. Earnings per share was 1.42.
| Revenue | 4.21B |
| Gross Profit | 1.35B |
| Operating Income | 428.10M |
| Pretax Income | 312.19M |
| Net Income | 330.67M |
| EBITDA | 633.14M |
| EBIT | 428.10M |
| Earnings Per Share (EPS) | 1.42 |
Balance Sheet
The company has 691.84 million in cash and 1.62 billion in debt, giving a net cash position of -927.03 million or -3.93 per share.
| Cash & Cash Equivalents | 691.84M |
| Total Debt | 1.62B |
| Net Cash | -927.03M |
| Net Cash Per Share | -3.93 |
| Equity (Book Value) | 2.71B |
| Book Value Per Share | 11.05 |
| Working Capital | 1.10B |
Cash Flow
In the last 12 months, operating cash flow was 702.80 million and capital expenditures -393.69 million, giving a free cash flow of 309.10 million.
| Operating Cash Flow | 702.80M |
| Capital Expenditures | -393.69M |
| Free Cash Flow | 309.10M |
| FCF Per Share | 1.31 |
Margins
Gross margin is 32.02%, with operating and profit margins of 10.16% and 7.85%.
| Gross Margin | 32.02% |
| Operating Margin | 10.16% |
| Pretax Margin | 7.41% |
| Profit Margin | 7.85% |
| EBITDA Margin | 15.03% |
| EBIT Margin | 10.16% |
| FCF Margin | 7.34% |
Dividends & Yields
This stock pays an annual dividend of 0.85, which amounts to a dividend yield of 3.33%.
| Dividend Per Share | 0.85 |
| Dividend Yield | 3.33% |
| Dividend Growth (YoY) | 308.57% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 66.72% |
| Buyback Yield | 0.65% |
| Shareholder Yield | 3.98% |
| Earnings Yield | 5.57% |
| FCF Yield | 5.20% |
Stock Splits
The last stock split was on June 21, 2024. It was a forward split with a ratio of 1.3.
| Last Split Date | Jun 21, 2024 |
| Split Type | Forward |
| Split Ratio | 1.3 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |